BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.00 Consensus Target Price from Brokerages
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12-month target price […]
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12-month target price […]
